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The rapid emergence and dissemination of antimicrobial-resistant microorganisms in ICUs worldwide constitute a
problem of crisis dimensions. The root causes of this problem are multifactorial, but the core issues are clear. The
emergence of antibiotic resistance is highly correlated with selective pressure resulting from inappropriate use of
these drugs. Appropriate antibiotic stewardship in ICUs includes not only rapid identification and optimal treatment
of bacterial infections in these critically ill patients, based on pharmacokinetic-pharmacodynamic characteristics, but
also improving our ability to avoid administering unnecessary broad-spectrum antibiotics, shortening the duration
of their administration, and reducing the numbers of patients receiving undue antibiotic therapy. Either we will be
able to implement such a policy or we and our patients will face an uncontrollable surge of very difficult-to-treat
pathogens.Introduction
Optimal antibiotic use is crucial in the critical care set-
ting, especially in an era of rising antibiotic resistance and
lack of new antimicrobial development [1-3]. Study results
indicate that 30% to 60% of antibiotics prescribed in ICUs
are unnecessary, inappropriate, or suboptimal [4-7]. Over-
prescribing and misprescribing antibiotics are undoubtedly
contributing to the growing challenges posed by antibiotic-
resistant bacteria, and epidemiological studies have clearly
demonstrated direct relationships between antibiotic con-
sumption and the emergence and dissemination of resist-
ant strains in hospitals and ICUs [7-20]. As defined by the
Society of Healthcare Epidemiology of America and Infec-
tious Diseases Society of America (IDSA) Joint Committee
on the Prevention of Antimicrobial Resistance in hospitals,
‘stewardship of antimicrobials is an apt descriptor of re-
lated activities that help optimize antimicrobial therapy,
ensuring the best clinical outcome for the patient while
lowering the risk of subsequent development of anti-
microbial resistance’ [14]. Thus, in-ICU antibiotic stew-
ardship encompasses rapid identification of patients with
bacterial infections, better empirical treatment selection,
using pharmacokinetic-pharmacodynamic (PK-PD) char-
acteristics to optimize antibiotic dosing and administra-
tion modalities, de-escalation once culture results become* Correspondence: charles-edouard.luyt@psl.aphp.fr
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numbers of patients treated unnecessarily.
Unfortunately, improving in-ICU antibiotic use is par-
ticularly difficult for three main reasons: infection severity
often precludes withdrawing or postponing antibiotics,
the complex decision-making process frequently involves
doctors with limited expertise, and it is difficult to ensure
disease-long continuity of care by the same medical team
24 hours a day, 7 days a week. Here, we review how in-
ICU antibiotic therapy could possibly be optimized and
rationalized.
Rapid identification of intensive care unit patients
with bacterial infections
Most published observational data suggest that the time to
appropriate antibiotic administration is a major outcome
determinant for ICU patients with severe bacterial infec-
tions. Indeed, each hour of delay in administering effective
antibiotics for septic shock is associated with measurably
increased mortality [6,21-25]. Thus, as strongly recom-
mended by all guidelines [26-29], obtaining biological speci-
mens should not postpone timely antibiotic administration
to patients with severe sepsis or septic shock.
However, owing to methodological concerns, the harm-
ful effects of inadequate therapy are not accepted by all
[30-36]. Because in-ICU signs and symptoms of infection
due to non-infectious causes are common, rushing to pre-
scribe antibiotics may mean that many uninfected patients
receive unnecessary treatment. In a quasi-experimental,
before-and-after, observational cohort study of patients. The licensee has exclusive rights to distribute this article, in any medium, for
time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0) applies to the data made available in this article,
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Hranjec and colleagues [32] postulated that delaying anti-
biotics for hemodynamically stable patients with suspected
infections (35% pneumonia) until they were objectively
documented would not worsen mortality. Notably, that
conservative approach was associated with lower all-cause
mortality, more initially appropriate therapy, and shorter
mean treatment duration than the aggressive strategy.
Thus, for clinically stable patients, that strategy might
achieve better antibiotic use without impacting prognosis.
Obtaining specimens for appropriate cultures before anti-
biotic administration is essential to confirm infection, iden-
tify responsible pathogens, and enable therapy de-escalation
in response to susceptibility profiles.
The inaccuracy of conventional approaches to diagnose
hospital-acquired infections (HAIs) and the impossibility of
those strategies to avoid antibiotic overprescription led some
investigators to hypothesize that using biological markers -
for example, C-reactive protein, soluble-triggering receptor
expressed on myeloid cells-1, or procalcitonin (PCT) -
might better identify true bacterial infections and facilitate
therapeutic decisions. However, although PCT is a good
marker of community-acquired infections (CAIs), it
does not seem to be for HAIs [37-41]. Indeed, blood PCT
concentrations can rise in various non-septic conditions:
major trauma, surgery, acute respiratory distress syn-
drome, multiorgan failure, post-transplantation rejection,
cardiogenic shock, severe burns, heat stroke, and so on.
Thus, high PCT concentrations the day sepsis is suspected
are non-contributory because increases that are attribut-
able to a prior non-infectious condition or active infection
cannot be distinguished [39,42,43]. Moreover, PCT can re-
main low in some microbiologically proven bacterial
infections, either because the infection remains con-
tained in a tissue compartment that can synthesize PCT
locally without systemic release, thereby explaining the
low serum level despite true infection, or because of
a 24- to 48-hour lag time in infection onset to peak
PCT release. Thus, intensivists are rightly reluctant to
rely exclusively on biological markers when severe infec-
tion is suspected [37,38,43-47].
Selection of initial antibiotic therapy
Owing to the emergence of multiresistant Gram-negative
bacilli (GNB) (for example, Pseudomonas aeruginosa,
extended-spectrum β-lactamase-producing Enterobacteri-
aceae, and carbapenemase-producing Klebsiella pneumo-
niae) and the increasing role of Gram-positive bacteria (like
methicillin-resistant Staphylococcus aureus, or MRSA), em-
pirical broad-spectrum antibiotics are justified for most
ICU patients with clinically suspected HAIs [25-27,48].
Regimen choice should be based on local antimicrobial sus-
ceptibility patterns and anticipated side effects while con-
sidering the antibiotics received within the preceding2 weeks and striving whenever possible not to use the
same classes [49-51]. Having current and frequently up-
dated knowledge of local bacteriological epidemiology in-
creases the likelihood of prescribing appropriate initial
antibiotics. Whether surveillance cultures could further
improve empirical treatment selection for ICU patients
with suspected hospital-acquired pneumonia (HAP) is still
debated but certainly should be weighed when difficult-
to-treat microorganisms abound, making initial choices
particularly risky [52,53]. Observational study results con-
firmed that initial regimens combining a broad-spectrum
β-lactam and an aminoglycoside increased the proportion
of appropriately treated patients compared with mono-
therapy or a combination of β-lactam and fluoroquinolone
[54,55]. Only patients with mildly or moderately severe,
early-onset infections and no specific risk factors (for ex-
ample, prolonged hospitalization, immunosuppression, or
recent prolonged antibiotics or a combination of these)
can receive a relatively narrow-spectrum drug, like a non-
pseudomonal third-generation cephalosporin.
For ICU patients admitted with health care-associated
or community-onset infections or CAIs, more restraints
for antimicrobial therapy selection are certainly possible.
For example, it is increasingly recognized that applying
current criteria for health care-associated pneumonia -
hospitalization for at least 2 days during the preceding
90 days, residence in a nursing home or extended-care
facility, home intravenous (antibiotics or chemotherapy)
therapy, and chronic dialysis or home wound care (or both)
during the preceding 30 days - as indications for broad-
spectrum antibiotics may lead to overtreatment of many
patients with pneumonia [>56-62]. To address this con-
ceptual limitation, investigators developed multiple risk-
assessment models that refine those criteria [61,63,64].
Available data suggest that the incidence of pathogens
resistant to the usual in-patient IDSA-American Thoracic
Society guideline-recommended antibiotic regimen (that
is, a non-pseudomonal cephalosporin and a macrolide)
is usually not significantly increased unless two or more risk
factors are present, with prior antibiotic use or hospitalization
and poor functional status being more important predic-
tors of resistant bacteria than nursing-home residence
alone [61]. Using such an algorithm could lead to
fewer pneumonia patients unnecessarily receiving broad-
spectrum antibiotics.
Within the past decade, the way clinical microbiology
laboratories identify microorganisms was revolutionized,
leaving behind slow traditional methods based on pheno-
type characteristics (for example, growth on defined media,
colony morphology, Gram staining, and biochemical reac-
tions) incurring significant diagnosis delay, in exchange
for new diagnostic techniques (real-time multiplex poly-
merase chain reaction and matrix-assisted laser desorp-
tion/ionization time-of-flight mass spectrometry) [65,66].
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and their antimicrobial resistance patterns (at least for
certain organisms), could undoubtedly promote earlier
therapy appropriateness and de-escalation [67]. Multiple
instrument platforms, marketed by well-established man-
ufacturers, are beginning to displace or complement (or
both) automated conventional phenotyping tools, provid-
ing accurate microbial identification from blood cultures
within 1 to 2 hours. Nevertheless, it is unlikely that any of
those new diagnostic methods will completely replace
phenotyping for antibiotic susceptibility testing in the near
future.
Pending the complete development of those above-
mentioned techniques, Bouza and colleagues [68] de-
scribed simple microbiology laboratory-accessible, rapid,
antimicrobial susceptibility E-tests directly on samples
(lower respiratory tract or other biological specimens) to
improve early appropriate in-ICU antimicrobial choices.
In a prospective randomized study of 250 patients with
microbiologically confirmed ventilator-associated pneu-
monia (VAP), the authors showed that reporting rapid
E-test-obtained antibiotic susceptibility of responsible
microorganisms to the treating physicians (mean ±
standard deviation: 1.4 ± 0.75 days post-sampling versus
4.2 days with standard methods) was associated with
fewer days of fever and antibiotics until VAP-episode
resolution, less antibiotic consumption, less Clostridium
difficile-associated diarrhea, lower antimicrobial costs,
and fewer days on mechanical ventilation (MV) [68].
Pharmacokinetic-pharmacodynamic-optimized
antimicrobial therapy
Reported findings demonstrated the need to individually
adjust the antibiotic target doses and administration mo-
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Figure 1 Pathophysiological changes commonly observed in critically
with permission from Elsevier Limited [75]. ECMO, extracorporeal membranPK and putative or documented pathogens’ susceptibilities,
as assessed by their minimal inhibitory concentrations
(MICs) [69-73]. Most investigators distinguish antimicro-
bials by their killing mechanism: concentration-dependent
(for example, aminoglycosides and fluoroquinolones) or time-
dependent (for example, β-lactams and carbapenem). The
most important PK-PD parameters are peak concentration/
MIC >8-10 and 24-hour area under the concentration
curve (AUC)/MIC >100-125 for aminoglycosides and
fluoroquinolones. For β-lactams and carbapenem, the blood
concentration should be maintained for >90-100% of the
between-dose interval above MIC, at least in the case of
severe infection [74,75]. However, it should be acknowl-
edged that the exact target for PK-PD-optimized therapy
remains elusive. Some antibiotics, such as fluoroquino-
lones and glycopeptides, are more complex and exhibit
both concentration- and time-dependent kill character-
istics where the best predictor of efficacy is the AUC/
MIC. Others, such as carbapenems, have a marked post-
antibiotic effect (that is, lead to a prolonged suppression
of bacterial growth even with antibiotic concentrations
below the MIC) [76,77].
ICU patients’ altered PK secondary to increased vol-
ume of distribution and decreased elimination can result
in insufficient serum aminoglycosides or β-lactam con-
centrations (or both) when standard doses are adminis-
tered, emphasizing the need to carefully monitor peak and
trough antibiotic levels when treating resistant pathogens,
respectively [5,78,79]. Antibiotic doses for ICU patients
derived from other patient groups are likely to be subopti-
mal because of significant antibiotic PK changes, particu-
larly volume of distribution and clearance. Organ support
techniques, including renal replacement therapy and
extracorporeal membrane oxygenation, increase PK vari-
ability (Figure 1) [80-82]. In a recent prospective studyness
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ICU patients receiving β-lactams for infection did not
achieve free antibiotic concentrations above their patho-
gens’ MICs during 50% and 100% (50% and 100% fT >
MIC, respectively) of the dosing interval (Figure 2) [5].
Frequently, higher than usually recommended antibiotic
doses or continuous or extended infusions (or a combin-
ation of these) are needed [5,70,71,73,79,83-85]. Interest-
ingly, use of prolonged infusion appeared to be associated
with a significant reduction in mortality and improvement
in clinical success when compared with intermittent bo-
luses in a recent meta-analysis of 29 studies (18 random-
ized controlled trials and 11 observational studies) with a
total of 2,206 patients [85].
Development of a priori dosing algorithms based on
MIC, creatinine clearance and weight, and the clinician-
specified AUC target might improve management of
these patients, obtaining more precise antibiotic use than
current guidelines [73,79,83,84,86]. Ultimately, adjusting
antibiotic doses based on pathogen MICs and daily free
antibiotic blood concentrations may reach optimized PK-
PD targets in most ICU patients. A therapeutic drug-
monitoring strategy, compared with traditional dosing
methods, might not only reduce clinical failure rates in
ICU patients but also prevent adverse events due to too
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Figure 2 Achievement of pharmacokinetic/pharmacodynamic targets
Data are expressed as percentage of patients achieving target. Doses for ea
in Table 3 of [5] with permission from Oxford Journals. 50% fT >MIC, free d
of the known or suspected pathogen for at least 50% of dosing interval; 50%
fourfold higher than the minimum inhibitory concentration of the known or
free drug concentration maintained above minimum inhibitory concentration
interval; 100% fT > 4 ×MIC, free drug concentration maintained above a conc
the known or suspected pathogen throughout the entire dosing interval.A double-blind randomized trial comparing 7 days of
doripenem three times a day (4-hour infusion of 1 gram)
with 10 days of imipenem-cilastin (1-hour infusion of 1
gram) for GNB VAP was prematurely stopped after ran-
dom assignment of 274 patients because of inferior effi-
cacy and higher day-28 all-cause mortality in the
subgroup of doripenem-treated, P. aeruginosa-infected
patients [89]. Despite longer doripenem infusions to
optimize targeted antibiotic concentrations above the
pathogens’ MICs during the 8-hour interval, this proto-
col performed more poorly, clearly documenting the risk
associated with a so-called PK-PD-optimized antibiotic
strategy when blood concentrations cannot be monitored
and adjusted to stay above the responsible pathogens’
MICs. Perhaps the treatment duration or concentrations
(or both) were sub-therapeutic for patients with elevated
creatinine clearance, clearly documenting the risk associ-
ated with a so-called PK-PD-optimized antibiotic strategy
when blood concentrations cannot be monitored and
adjusted to stay above the MIC of the responsible
pathogens [90].
For patients on MV, aerosolized antibiotics delivered via
an efficient system, synchronized with inspiration, achieved
airway drug concentrations 100- to 300-fold higher than
the MICs of most bacteria, including multidrug-resistant
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ch antibiotic are given as a median. This figure was drawn from data
rug concentration maintained above minimum inhibitory concentration
fT > 4 ×MIC, free drug concentration maintained above a concentration
suspected pathogen for at least 50% of dosing interval; 100% fT >MIC,
of the known or suspected pathogen throughout the entire dosing
entration fourfold higher than the minimum inhibitory concentration of
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on MV and lower the pressure for selection of new
resistant organisms, as shown in a recent, double-blind,
placebo-controlled study of 42 ICU patients who required
prolonged MV and who were colonized or infected (or
both) with potentially difficult-to-treat pathogens (for ex-
ample, MRSA and non-fermenting GNB) [96]. However,
larger clinical trials must confirm those findings before
that strategy can be recommended, in light of its poten-
tially deleterious impact on the local epidemiology when
used for all ICU patients over prolonged periods [97-99].
Antimicrobial therapy de-escalation
The need to ensure that ICU patients with true bacterial
infections receive prompt and appropriate antibiotics
can lead to many more patients receiving antimicrobials
than necessary, because of non-specific clinical signs of
infection. This is particularly true for HAP/VAP, which
represents the first in-ICU indication for starting antibi-
otics. Thus, regardless of the diagnostic strategy used for
suspected HAP/VAP, serial clinical and microbiological
evaluations are highly relevant to re-assess therapy after
48 to 72 hours and to stop it if infection is unlikely
[48,100]. To accomplish that goal, each ICU should de-
sign its own diagnostic decision-tree strategy to manage
patients with clinically suspected HAP/VAP to identify
those with a low probability of infection, whose therapy
can be discontinued when infection appears improbable
[27,48]. At least, antibiotics should be withdrawn when
the following three criteria are fulfilled on day 3: (a) the
clinical diagnosis of pneumonia is unlikely - no definite
infiltrates seen on repeat chest radiography and only one of
the following three findings is present: temperature greater
than 38.3°C, leukocytosis (greater than 12,000/mm3) or
leukopenia (less than 4,000/mm3), or purulent tracheobron-
chial secretions - or an alternative non-infectious diagnosis
is confirmed; (b) non-significant tracheobronchial aspirate
culture results; and (c) no severe sepsis or shock [101]. Dir-
ect examination of distal pulmonary samples collected by
bronchoalveolar lavage with or without a bronchoscope
and quantitative culture results have consistently yielded
fewer microorganisms growing above the diagnostic thresh-
old than qualitative tracheal aspirate cultures [48,102].
Pertinently, when therapeutic decisions were based on those
results, compared with the clinical approach, fewer pa-
tients received antibiotics that were of a potentially nar-
rower spectrum, thereby limiting the emergence and
dissemination of drug-resistant strains and minimizing
antibiotic-related toxicity [103].
For many ICU patients with infections (including late-
onset infections), therapy can be de-escalated, once re-
spiratory tract, blood, or other specimen culture results
become available, if no resistant organism (for example,
P. aeruginosa, Acinetobacter spp., or MRSA) is recoveredor because the isolated pathogen is sensitive to a narrower-
spectrum antibiotic than that prescribed empirically
[26,27,48]. For example, if MRSA is not found, vancomycin
and linezolid should be stopped unless the patient is
allergic to β-lactams or has developed an infection
with Gram-positive bacteria susceptible only to them. Very-
broad-spectrum agents (like carbapenems, piperacillin-
tazobactam, and cefepime) should also be restricted to
patients whose infectious pathogens are susceptible only
to them. Because fluoroquinolones have been associated
with the emergence of resistant strains, their in-ICU use
probably should be discouraged [104,105]. Antifungals
should never be prescribed for Candida isolated from re-
spiratory secretions alone [106]. However, clinicians
should know that, when third-generation cephalosporins
are chosen to treat infections caused by Enterobacteriacaea
with inducible β-lacatamase (Enterobacter, Citrobacter,
Morganella morganii, indole-positive Proteus, or Serratia
spp.), the emergence of resistant variants may lead to treat-
ment failure. Unfortunately, study results showed that de-
escalation, though not associated with any adverse outcomes,
was not consistently applied in many ICUs [107-111].
The two most commonly cited reasons to prescribe
combined antibiotics for the entire treatment duration are
to achieve synergy and to prevent the emergence of resist-
ant strains. However, antibiotic synergy has been shown to
be valuable only in vitro and in patients with neutropenia,
bacteremia, or a greater than 25% probability of death
[25,112-122]. Randomized controlled trial results on com-
bined therapy showed its benefit to be inconsistent or null,
even when they were pooled in meta-analyses or when
analysis was restricted to P. aeruginosa-infected patients
[113,121,123,124]. Importantly, such regimens did not
prevent the emergence of antimicrobial resistance during
therapy and were associated with significantly more
nephrotoxicity [121]. Those observations were confirmed
in a randomized, open-label trial on 600 patients meeting
criteria for severe sepsis or septic shock: combined mero-
penem and moxifloxacin versus meropenem alone did not
achieve less organ failure or better survival or any second-
ary endpoints [113]. Based on those data, most patients’
therapy could be safely switched to monotherapy after 3 to
5 days, provided that the initial therapy was appropriate,
the clinical course evolved favorably, and microbiological
data did not indicate difficult-to-treat microorganisms,
with high in vitro MICs, as can be observed for some non-
fermenting GNB.
Shortening treatment duration
Although shortening the duration of antibiotic adminis-
tration for ICU patients may represent the most power-
ful strategy to reduce antibiotic impact on resistance
emergence, most guidelines still recommend relatively
prolonged or imprecise durations [26,28,125,126]. Efforts
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fied by study results on the natural history of therapeutic
responses. Most patients who had CAIs or HAIs, includ-
ing VAP, and who received appropriate antimicrobial
therapy had good clinical responses within the first 6 days
[127-129]. Prolonged therapy facilitates colonization with
antibiotic-resistant bacteria, which may precede recurrent
infectious episodes.
Results of a multicenter, randomized controlled trial on
401 patients with microbiologically proven VAP showed
that their clinical outcomes were similar to those of pa-
tients receiving appropriate empirical therapy for 8 or
15 days [130]. Relapse rates for short-duration therapy
tended to be higher when P. aeruginosa or Acinetobacter
spp. was the causative agent, but clinical outcomes were
indistinguishable. Those observations were confirmed by
trials that evaluated an antibiotic discontinuation policy
for patients with other infections [111,131-138].
Many clinicians remain reluctant to prescribe fewer
days of antibiotics for patients with severe HAIs and
prefer tailoring antibiotic duration to the ensuing clinical
course or using serial biomarker (for example, PCT) de-
terminations (or both). The rationale for using the latter to
customize treatment duration relies on evidence that the
inflammatory response is often proportional to infection
severity. When the response is absent or mild, antibiotics
might logically be discontinued earlier. Thus, adapting
treatment duration to PCT kinetics seems reasonable and
was demonstrated to be useful in several randomized trials,
including seven in the ICU, targeting patients with acute
respiratory infections [37,41,139-143]. The largest of those
studies was the PRORATA trial that included 621 ICU pa-
tients; 67% of these patients were on MV, 50% had CAIs,
and 50% had HAIs, and half of them had septic shock [37];
patients in the PCT group had significantly more (mean ±
standard deviation) days without antibiotics than controls
(14.3 ± 9.1 versus 11.6 ± 8.2; absolute difference 2.7 days;
95% confidence interval 1.4 to 4.1; P < 0.0001), and this
lower antibiotic consumption was not associated with
poorer outcomes. Furthermore, regardless of infection site
and the infectious agent, results were consistent (Figure 3).
In summary, shortening the treatment duration for ICU
patients with infections is possible and not detrimental for
most of them. Indeed, the diversity of patients enrolled in
those trials and the consistency of the findings suggest
that the conclusions may be applicable to most critically
ill patients who develop infections, including severe sepsis
or septic shock, with the possible exception of those who
are immunosuppressed, those who are infected with mul-
tiresistant microorganisms or whose course deteriorates
despite treatment, or those whose initial regimen was in-
appropriate for the responsible pathogens. That strategy
should help contain health-care costs and limit in-ICU
emergence of bacterial resistance.Implementing a structured antibiotic stewardship
program
Optimizing in-ICU antimicrobial therapy is difficult. No
single measure alone can succeed, emphasizing the need
to devise a structured antibiotic stewardship program.
Unfortunately, the exact set of key interventions essential to
this multifaceted and multidisciplinary ‘care bundle’ remains
unknown, as do the factors contributing to its success
[1,3,109,144-146]. The interventions should be packaged so
that compliance is readily assessable and achievable, which
usually means that each bundle includes no more than five
to eight interventions. Table 1 provides an example of anti-
biotic stewardship for patients with VAP. Successful imple-
mentation requires an interdisciplinary team, educational
interventions, system innovations, process indicator evalu-
ation, and feedback to health-care workers. Several studies
using quasi-experimental designs confirmed the useful-
ness of such a strategy to optimize in-ICU antibiotic
stewardship, but not all designs proved to be effective
[111,147,148]. As the results of a recent study [149]
showed, simply having a reference checklist, without a ro-
bust implementation-and-adherence strategy, is unlikely
to improve patient outcomes [149,150].
Computerized decision-support programs linked to
electronic patient records can facilitate the dissemination
of information to physicians for immediate use in thera-
peutic decision making and improving quality of care
[151-154]. Partially or non-automated protocols, often in-
stigated by hospital-based quality-improvement teams, also
had demonstrated efficacy [154-157]. A prospective inter-
vention of having an infectious disease specialist interact
regularly with the medical ICU team was conducted to
assess guideline compliance and antibiotic and health-care
costs; it achieved significantly reduced use of extended-
spectrum penicillins, carbapenems, vancomycin, and
metronidazole [157]. Specifically, the intervention group
had a significantly lower rate of treatments not corre-
sponding to guidelines, with fewer MV days, shorter stays,
and lower in-hospital mortality. Moreover, $89,944 was
saved for early antibiotic discontinuation alone [157].
Conclusions
The high antibiotic resistance observed in ICU patients
who develop infections limits treatment options and jus-
tifies using regimens combining several broad-spectrum
antibiotics, even when the presumed infection probabil-
ity is low, because initial inappropriate therapy has been
linked to poor prognoses. More than its economic impact,
this ‘spiraling empirical’ practice increasingly leads to un-
due antibiotic administration to many ICU patients with-
out true infections, paradoxically causing the emergence
of more antibiotic-resistant microorganisms causing infec-
tions that, in turn, are associated with heightened mortal-
ity and morbidity. Therefore, antibiotic therapy for ICU
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Figure 3 Duration of antibiotic treatment of the first episode in the PRORATA trial, according to infection site. White bars indicate
patients included in the control group. Hatched bars indicate patients included in the procalcitonin-guided group. This figure was drawn from
data in Table 2 of [37] with permission from Elsevier Limited. CAP, community-acquired pneumonia; PRORATA, Use of Procalcitonin to Reduce
Patients’ Exposure to Antibiotics in Intensive Care Units; UTI, urinary tract infection; VAP, ventilator-associated pneumonia.
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process: the first involves administering broad-spectrum
antibiotics to avoid inappropriate treatment of true bacter-
ial infections, and the second focuses on trying to achieve
the first without antibiotic overuse or abuse. In general,
the first goal can be accomplished by rapidly identifying
patients with infection and starting empirical therapy
likely to treat the institution’s most common etiological
agents. This strategy requires that initial antibiotic choicesTable 1 A personal care bundle for optimizing antimicrobial t
associated pneumonia
Antibiotic stewardship items Rationale
Step 1: Obtain bronchoalveolar specimens
for Gram staining and cultures before
introducing new antibiotics.
Every effort should be m
for direct microscope ex
Step 2: Start antibiotics less than 2 hours
after bronchoalveolar lavage.
Time to appropriate ant
care unit patients with s
Step 3: Start therapy using broad-spectrum
antibiotics unless no risk factors for resistant
pathogens are present.
Owing to the emergenc
ESBL-producing GNB), e
clinically suspected VAP
Step 4: Stop therapy on day 3 if infection
becomes unlikely.
Antibiotics can be disco
on negative cultures and
Step 5: Use pharmacokinetic-pharmacodynamic
data to optimize treatment.
Clinical and bacteriologi
according to pharmacok
Step 6: Streamline antibiotic therapy by
using narrower-spectrum antibiotics once
the etiological agent is identified.
For many patients with
once respiratory tract an
bacterium (for example,
aureus) was not recover
antibiotic than that used
Step 7: Switch to monotherapy on days 3 to 5. Using a two-antibiotic re
initial therapy was appro
exclude difficult-to-treat




which may precede recu
ESBL, extended-spectrum β-lactamase; GNB, Gram-negative bacilli; VAP, ventilator-abe guided by local antibiotic resistance patterns and la-
boratory test results (including Gram staining), rapidly
yielding identities of likely responsible pathogens. The sec-
ond aim involves stopping therapy when the probability of
infection is low, focusing and narrowing treatment once
the microorganism is known, switching to monotherapy
after day 3 whenever possible, and shortening treatment
to 7 to 8 days for most patients, based on the clinical re-
sponse and bacteriology findings. Therefore, every effortreatment for intensive care unit patients with ventilator-
ade to obtain reliable specimens from the specific infection site
amination and cultures in order to enable de-escalation.
imicrobial administration is a major outcome determinant for intensive
evere bacterial infections.
e of multiresistant GNB (for example, Pseudomonas aeruginosa and
mpirical broad-spectrum antibiotics are justified for most patients with
.
ntinued very early when VAP diagnosis becomes highly unlikely based
clinical course and the elimination of an extrapulmonary infection.
cal outcomes can be improved by optimizing the therapeutic regimen
inetic-pharmacodynamic properties of the selected agents.
VAP, including those with late-onset infections, therapy can be narrowed
d blood culture results become available, either because an anticipated
P. aeruginosa, Acinetobacter spp., or methicillin-resistant Staphylococcus
ed or because the isolated pathogen is sensitive to a narrower-spectrum
initially.
gimen for more than 3 to 5 days has no clinical benefits, provided that
priate, the clinical course evolves favorably, and microbiological data
microorganisms.
istration for patients with VAP has achieved good outcomes with less
Prolonged therapy leads to colonization with antibiotic-resistant bacteria,
rrent VAP episodes.
ssociated pneumonia.
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specific suspected infection site in each patient for dir-
ect microscope examination and cultures in order to de-
escalate antibiotics.
Key messages
 The rapid in-ICU emergence and dissemination of
multidrug-resistant microorganisms worldwide
constitute a problem of crisis dimensions that is
linked directly to inappropriate antimicrobial use.
 Appropriate antibiotic stewardship is a two-stage
process.
 Stage I includes rapidly identifying patients with
infection, starting an empirical regimen likely to
treat the institution’s most common etiological
agents, and optimizing bacterial killing by adjusting
antibiotic doses and administration modalities based
on PK-PD characteristics.
 Stage II involves stopping therapy in patients
unlikely to have infections, focusing and narrowing
treatment once the responsible pathogen is known,
switching to monotherapy after day 3 whenever
possible, and shortening antibiotic administration to
7 to 8 days for most patients, based on the
therapeutic response and microbiology data.
 Any antibiotic stewardship program should be
implemented in a structured manner and requires
an interdisciplinary team, educational interventions,
system innovations, process indicator evaluation,
and feedback to health-care workers.
Note
This article is part of a series on Antibiotic resistance
in the ICU, edited by Steven Opal. Other articles in
this series can be found at http://ccforum.com/series/
antibioticresistance.
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